Get the Stockscreener App
7.3857
0.67%
-0.0543
CorMedix Inc stock is traded at $7.3857, with a volume of 1.32M.
It is down -0.67% in the last 24 hours and down -38.31% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$7.44
Open:
$7.36
24h Volume:
1.32M
Relative Volume:
0.40
Market Cap:
$582.25M
Revenue:
$65,400
Net Income/Loss:
$-46.34M
P/E Ratio:
-8.0279
EPS:
-0.92
Net Cash Flow:
$-38.74M
1W Performance:
+9.00%
1M Performance:
-38.31%
6M Performance:
-36.40%
1Y Performance:
-39.92%
1-Day Range:
$7.145
$7.52
1-Week Range:
$6.55
$7.59
52-Week Range:
$5.60
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
7.39 | 586.19M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.00 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.41 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.53 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.01 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.15 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Jun-30-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption? - Yahoo Finance
CorMedix director Dillione sells $68,800 in shares By Investing.com - Investing.com Nigeria
CorMedix director Dillione sells $68,800 in shares - Investing.com
Guidance Update: What is the next catalyst for Pyxis Tankers Inc Equity WarrantWeekly Trade Report & High Return Trade Opportunity Guides - baoquankhu1.vn
Where Cormedix Stands With Analysts - Benzinga
RBC Capital Lowers Price Target for CRMD, Maintains Outperform R - GuruFocus
CorMedix (CRMD) price target decreased by 11.28% to 17.19 - MSN
CorMedix Investors Seek First OK Of Governance Reform Deal - Law360
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? - sharewise.com
Witnessing An Insider Decision, Joseph Todisco Exercises Options Valued At $93K At Cormedix - Benzinga
Is CorMedix (CRMD) Offering An Opportunity After Its Recent 43% Share Price Slide - Yahoo Finance
CorMedix Inc (NASDAQ:CRMD) Exemplifies a High-Growth Stock Screen Methodology - Chartmill
Market Review: Will CorMedix Inc benefit from seasonality2025 Sector Review & Weekly Setup with ROI Potential - baoquankhu1.vn
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 - Finviz
Sentiment Review: Whats the profit margin of PGHLPortfolio Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
CorMedix (CRMD) Is Down 11.1% After CEO Becomes Chair And Sets 2026 Revenue TargetHas The Bull Case Changed? - simplywall.st
Breaking Update: Steven Lefkowitz Engages In Options Exercise At Cormedix Realizing $22K - Benzinga
Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings? - Yahoo Finance
Weekly Recap: Is CorMedix Inc benefiting from interest rate changesJuly 2025 WrapUp & Daily Profit Focused Screening - baoquankhu1.vn
Is It Time To Reassess CorMedix (CRMD) After The Sharp Recent Share Price Slide - Sahm
Death Cross: Can CorMedix Inc stock deliver 10 annual returnsPortfolio Performance Summary & Daily Chart Pattern Signal Reports - Bộ Nội Vụ
CorMedix (NASDAQ:CRMD) Shareholders Are Still up 63% Over 3 Years Despite Pulling Back 37% in the Past Week - 富途牛牛
CorMedix (CRMD) Valuation After New Leadership Moves And 2026 Revenue Guidance - Sahm
Why Did CRMD Stock Crash 28% Today? - Asianet Newsable
CRMD: 2026 will be a transitional year, with growth driven by new indications and pipeline catalysts - TradingView — Track All Markets
CorMedix stock price target lowered to $15 by Leerink Partners By Investing.com - Investing.com India
CorMedix stock price target lowered to $15 by Leerink Partners - Investing.com Nigeria
CorMedix: The Post-TDAPA Hangover Arrived Early (Rating Downgrade) (NASDAQ:CRMD) - Seeking Alpha
How sustainable is CorMedix Inc. stock dividend payoutWeekly Trading Summary & Precise Buy Zone Identification - Улправда
Asset turnover of CorMedix Inc. – HAM:19KA - TradingView — Track All Markets
CorMedix (CRMD) Is Down 35.4% After Cutting 2026 Revenue Outlook And Reshuffling Leadership - simplywall.st
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations - The Globe and Mail
CorMedix Faces A Hard Reset As CMS Reimbursement Headwinds Emerge (CRMD) - Seeking Alpha
Are Investors Undervaluing CorMedix (CRMD) Right Now? - Yahoo Finance
CorMedix Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
How Recent Q3 Updates Are Shaping The CorMedix (CRMD) Investment Story - Yahoo Finance
Why CorMedix (CRMD) Is Down 35.4% After Cutting 2026 Guidance And Revamping Its Leadership Structure - Yahoo Finance
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Sahm
CorMedix stock rises after-hours: CEO locks in chairman seat, bigger paycheck and rich severance - MSN
CorMedix Stock Rises After-Hours: CEO Locks In Chairman Seat, Bigger Paycheck And Rich Severance - Stocktwits
CorMedix Inc.Common Stock (NQ: CRMD - FinancialContent
What sentiment indicators say about CorMedix Inc. stockJuly 2025 Levels & Technical Confirmation Alerts - ulpravda.ru
Truist Securities lowers CorMedix stock price target on weaker revenue outlook By Investing.com - Investing.com South Africa
Breakout Move: Will CorMedix Inc. stock maintain growth storyDay Trade & Growth Focused Investment Plans - ulpravda.ru
A Look At CorMedix (CRMD) Valuation After 2026 Guidance Shift And Executive Changes - Yahoo Finance
Why is CorMedix stock crashing today: is it worth buying on the dip? - CryptoRank
Truist Securities lowers CorMedix stock price target on weaker revenue outlook - Investing.com Australia
CorMedix Therapeutics Appoints Joseph Todisco as Chairman, Extends CEO Contract - citybiz
CorMedix shares fall as 2026 revenue outlook disappoints (update) - MSN
Cormedix: Market Overreaction to 2026 Guidance Creates Undervalued Buy Opportunity - TipRanks
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
2.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):